FindTrial
Sign In

A bidirectional clinical study evaluating the efficacy of rituximab in the treatment of refractory minimal change disease

A bidirectional clinical study evaluating the efficacy of rituximab in the treatment of refractory minimal change disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097965
Enrollment
Unknown
Registered
2025-02-27
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimal change disease

Interventions

Retrospective cohort:None
Prospective cohorts:None

Sponsors

Southern Medical University Southern Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Male/Female aged 18-75; 2.Confirmed refractory nephrotic syndrome according to KDIGO guideline; 3.Voluntary signing of informed consent/informed waiver; 4.Renal biopsy confirmed minimal change disease;

Exclusion criteria

Exclusion criteria: 1.Secondary minimal change disease; 2.Pregnant woman; 3.receiving renal replacement therapy (hemodialysis, peritoneal dialysis, renal transplantation); 4.Combined with severe coronary heart disease, advanced malignant tumors, and other diseases with a life expectancy of less than 1 year; 5.Important clinical data are missing; 6.Patients deemed unsuitable for participation in this study by the investigator;

Design outcomes

Primary

MeasureTime frame
Proportion of patients with complete remission at week 52;Proportion of patients who relapsed before 52 weeks;—

Countries

China

Contacts

Public ContactDiankun Liu

Southern Medical University Southern Hospital

tennisldk@163.com+86 20 6278 7120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026